AS Bravo PharmaceuticalsRegistered
Annual report for 2025 not filed.
Qualified audit opinion. 2019 report: Qualified.
Key figures
28 873 €+44,8%
Revenue 2024
+5,2%
Average annual growth 2019–2024
Ratios
2024−246,5%
Profit margin
−234,4%
EBITDA margin
14,7%
Equity ratio
0,2×
Current ratio
−170,3%
Return on equity
473 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 0 € | 2 | 923 € |
| Q1 2026 | 0 € | 2 | 2826 € |
| Q4 2025 | 0 € | 1 | — |
| Q3 2025 | 0 € | 1 | 1651 € |
| Q2 2025 | 0 € | 1 | 5656 € |
| Q1 2025 | 3443 € | 1 | 2901 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2019–2024
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Balance sheet — assets | ||||||
| Total current assets | 96 961 | 47 456 | 62 375 | 56 781 | 57 561 | 46 661 |
| Total non-current assets | 69 942 | 251 515 | 266 505 | 250 602 | 241 511 | 237 898 |
| Total assets | 166 903 | 298 971 | 328 880 | 307 383 | 299 072 | 284 559 |
| Balance sheet — liabilities and equity | ||||||
| Current liabilities | 8554 | 56 507 | 143 729 | 109 217 | 186 118 | 242 772 |
| Non-current liabilities | 40 042 | 0 | 0 | 0 | 0 | — |
| Total liabilities | 48 596 | 56 507 | 143 729 | 109 217 | 186 118 | 242 772 |
| Share capital | 50 000 | 50 200 | 50 200 | 163 337 | 163 337 | 335 337 |
| Retained earnings of previous periods | 89 666 | 64 707 | 16 664 | −40 649 | −140 771 | −225 983 |
| Profit for the year | −24 959 | −48 043 | −57 313 | −100 122 | −85 212 | −71 167 |
| Reserves and other equity | 3600 | 175 600 | 175 600 | 175 600 | 175 600 | 3600 |
| Total equity | 118 307 | 242 464 | 185 151 | 198 166 | 112 954 | 41 787 |
| Income statement | ||||||
| Sales revenue | 22 429 | 52 458 | 30 158 | 4775 | 19 945 | 28 873 |
| Operating profit | −24 947 | −42 621 | −57 444 | −100 253 | −85 307 | −71 298 |
| EBITDA | −23 651 | −40 914 | −54 727 | −96 615 | −82 472 | −67 684 |
| Profit before income tax | −24 959 | −48 043 | −57 313 | −100 122 | −85 212 | −71 167 |
| Profit for the reporting year | −24 959 | −48 043 | −57 313 | −100 122 | −85 212 | −71 167 |
| Labour costs | 24 189 | 30 462 | 30 462 | 30 462 | 31 526 | 33 308 |
| Depreciation of non-current assets | 1296 | 1707 | 2717 | 3638 | 2835 | 3614 |
| Other indicators | ||||||
| Employees | 2 | 2 | 2 | 2 | 2 | 2 |
| Calculated dividend | — | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
Click a node to see its other connections.
CompanyPersonShareholderOther roleAdditional link
Annual reportsPDF, XBRL
Loading list of reports…
Source: e-Business Register (RIK). Files open/download directly from the official register.
Related companies
Same activity — Other human health activities n.e.c.